PPA
RGLS

Parametric Portfolio Associates’s Regulus Therapeutics RGLS Stock Holding History

Parametric Portfolio Associates’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-114
Closed -$150K – 3324
2015
Q2 		$150K Buy
+114
New +$184K ﹤0.01% 3823

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Parametric Portfolio Associates's RGLS Position: Q3 2015 in Review

Parametric Portfolio Associates sold out of Regulus Therapeutics (RGLS) in Q3 2015, closing a stake of 114 shares — an estimated $150K sold.

Parametric Portfolio Associates first reported a position in RGLS in Q2 2015 and held it in 1 quarter. The position peaked at $150K in Q2 2015. 92 funds tracked by Wall St. Rank hold RGLS as of Q3 2015.

  • Parametric Portfolio Associates reported no remaining Regulus Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Parametric Portfolio Associates sold 114 Regulus Therapeutics shares in Q3 2015, an estimated $150K.
  • Parametric Portfolio Associates first reported a position in Regulus Therapeutics in Q2 2015 and held it in 1 quarter.
  • Parametric Portfolio Associates's Regulus Therapeutics position peaked at $150K in Q2 2015.
  • 92 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2015.

Based on Parametric Portfolio Associates's 13F filing for Q3 2015, filed 16 Nov 2015.